Sanofi news and updates
Sanofi SA launches recall for Auviq devices both 0.15
Sanofi just announced a recall for Auviq devices both 0.15 and 0.30 due to possible incorrect dosage administration.
Jan 1, 2015 | bayareaallergy.comAimmune Therapeutics Inc. partnered with Sanofi Genzyme on Oct 16th 17'.
-- On October 16, 2017, Aimmune entered into a clinical collaboration with Regeneron (REGN) and its strategic alliance collaborator Sanofi (SNY) to study AR101 treatment with adjunctive *dupilumab in peanut-allergic patients in a Phase 2 clinical trial.
Jan 1, 2017 | businessinsider.comSanofi Genzyme acquired Sanofi Genzyme for $20.1B on Feb 3rd 22'.
Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a company-wide rebranding.
Jan 1, 2022 | cafepharma.comSebia Group partnered with Sanofi Genzyme on Jan 14th 20'.
In vitro diagnostic firm Sebia announced Tuesday it is partnering with Sanofi to develop a diagnostic test to mitigate possible interference from Sanofi's investigational antibody, isatuximab, in patients with multiple myeloma.
Jan 1, 2020 | 360dx.comSanofi Genzyme partners with Agilent Technologies, Inc.
Regeneron and Sanofi developed Libtayo and partnered with Agilent for the use of PD-L1 IHC 22C3 pharmDx to evaluate PD-L1 expression in patients in the pivotal EMPOWER-Lung 1 clinical trial.
Jan 1, 2021 | selectscience.netNurix Therapeutics, Inc. partnered with Sanofi Genzyme on Jan 7th 21'.
Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.
Jan 1, 2021 | globenewswire.comAdagene Inc. partners with Sanofi Genzyme
Adagene, which is on a quest to produce immunotherapies that don’t attack healthy cells, is partnering with Sanofi for up to four “safe” antibody candidates in oncology.
Jan 1, 2022 | fiercebiotech.comSanofi Genzyme hired Pucci as Executive Vice President and Head of Human Resources on Jan 1st 09'.
Mr. Pucci joined Sanofi in 2009 as Executive Vice President and Head of Human Resources, and has substantially transformed the human resources function and supported Sanofi through a period that saw considerable change in the company.
Jan 1, 2018 | globenewswire.comRoberto Pucci retires from Sanofi Genzyme
Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1 st Paris - July 26, 2018 - Roberto Pucci, Head of Human Resources, will retire from Sanofi after more than 9 years of service with the company.
Jan 1, 2018 | globenewswire.comSanofi Genzyme invests into Owkin Inc in $180M
Parisian AI biotech startup Owkin has received a $180 million investment from multi-national pharmaceutical giant Sanofi.
Jan 1, 2021 | tech.euDarioHealth Corp partners with Sanofi Genzyme
French pharmaceutical company Sanofi struck a $30 million, five-year agreement with digital health company DarioHealth.
Jan 1, 2022 | medtechdive.comSanofi Genzyme is developing digital health solutions for Dario's platform
DarioHealth's deal with Sanofi will see the companies working together to develop digital health solutions for Dario's platform.
Jan 1, 2022 | fiercehealthcare.comSanofi Genzyme integrates with DarioHealth Corp
Under the terms of the five-year deal, Sanofi digital health apps will be integrated into Dario’s platform and Sanofi’s sales muscle will be deployed to market the combined offering.
Jan 1, 2022 | pharmaphorum.comSanofi Genzyme is developing SARS-CoV-2 vaccine
BARDA and Sanofi Pasteur, the vaccines global business unit of Sanofi, are expanding their collaboration to develop a SARS-CoV-2 vaccine.
Jan 1, 2020 | globalbiodefense.comSanofi Genzyme merged with Aventis on Jan 1st 09'.
Throughout its history, the company has experienced a number of transformations, the latest of which was in 2009, when Sanofi merged with Aventis.
Jan 1, 2022 | 1000logos.netSanofi Genzyme partners with Enable Injections Inc.
While Blackstone has provided some financing to support the studies, Sanofi partnered with Enable Injections, a drug delivery technology company for subcutaneous formulation delivery.
Jan 1, 2022 | biospace.comSanofi Genzyme is developing clinical programme and retain full rights and control of Sarclisa
Sanofi will continue to fully manage the clinical programme and retain full rights and control of Sarclisa.
Jan 1, 2022 | europeanpharmaceuticalreview.comSanofi Genzyme partners with The Blackstone Group
Sanofi ( SNY ) was advancing by more than 2% after saying it is partnering with Blackstone ( BX ) to boost the clinical development of Sarclisa, a treatment for multiple myeloma.
Jan 1, 2022 | nasdaq.comSanofi Genzyme partnered with Seagen Inc. on Mar 16th 22'.
Having first teamed up with Immunogen almost 20 years ago, Sanofi has now joined forces with Seagen to jointly fund and develop three anti-cancer ADCs.
Jan 1, 2022 | fiercebiotech.comSanofi Genzyme goes public
Sanofi had previously planned to list the business via an initial public offering, but is now pursuing a spinoff.
Jan 1, 2022 | financialpost.comSanofi Genzyme recognized as No. 27 on The DiversityInc Top 50 Companies for Diversity list in 2021
Sanofi ranked No. 27 on The DiversityInc Top 50 Companies for Diversity list in 2021.
Jan 1, 2022 | diversityinc.comPrellis Biologics partnered with Sanofi Genzyme on Mar 22nd 22'.
SAN FRANCISCO, March 22, 2022--Prellis Biologics has entered into a collaboration and license option agreement with Sanofi.
Jan 1, 2022 | yahoo.comSanofi Genzyme launched ASMDFacts on Feb 12th 22'.
Get the information you need In addition to information available from NNPDF, Sanofi also recently launched a new website called ASMDFacts.com with information for both patients and clinicians.
Jan 1, 2022 | nnpdf.orgSanofi Genzyme invests into assets : mRNA facilities
According to Bloomberg, Sanofi will invest the funds over the next several years to build out its mRNA facilities and programs.
Jan 1, 2022 | biospace.comSanofi Genzyme receives award 2022 Distinguished Corporate Partner Award
In recognition of its ongoing support and partnership, AMGA has named Sanofi as the recipient of its 2022 Distinguished Corporate Partner Award.
Jan 1, 2022 | amga.orgSanofi Genzyme launched enterprise-wide collaboration to advance regulatory submissions on Jan 1st 19'.
Lately in 2019, Sanofi and Aetion launched enterprise-wide collaboration to advance regulatory submissions using real-world evidence.
Jan 1, 2021 | globalmarketstudies.comSanofi Genzyme hired Viviane Monges as Chair of the Supervisory Board on Jan 1st 21'.
In 2021, Sanofi announced several critical steps in this journey with the unveiling of the creation of EUROAPI and the appointment of Karl Rotthier as its CEO in January, the appointment of Viviane Monges as Chair of the Supervisory Board in July and the finalization of the carve-out in December 2021.
Jan 1, 2022 | sanofi.comSanofi Genzyme is developing COVID-19 vaccine
ATS’s corporate sponsors also include vaccine giant Merck, CSL Behring, which partnered AstraZeneca to produce its COVID-19 vaccine, and Novartis, which like Sanofi partnered with Pfizer to produce its COVID-19 vaccine.
Jan 1, 2022 | thekapnobatai.comSanofi Genzyme is developing novel antibody-drug conjugates on Mar 16th 22'.
Sanofi and Seagen announced on March 16, 2022, an exclusive collaboration agreement to design, develop, and commercialize novel antibody-drug conjugates (ADCs).
Jan 1, 2022 | pharmtech.comSanofi Genzyme hires Hudson as pharmaceuticals president
Hudson joined Sanofi at the start of September after previously serving as Novartis’ pharmaceuticals president.
Jan 1, 2019 | learningclue.euOrange Group partners with Sanofi Genzyme
Orange has joined forces with Sanofi, Capgemini and Generali to launch Future4care, a start-up accelerator which aims to facilitate the rapid deployment of e-health solutions and their availability on the market.
Jan 1, 2021 | orange.comScience 37, Inc. partners with Sanofi Genzyme
Science 37 has partnered with big names in pharma, such as Sanofi and Novartis, and remains one of the major players in the virtual trial space.
Jan 1, 2022 | anjusoftware.comSanofi Genzyme partnered with IGM Biosciences, Inc. on Mar 29th 22'.
Sanofi also announced on Tuesday a partnership with U.S company IGM Biosciences in the field of treatments for oncology, immunology and inflammation.
Jan 1, 2022 | medicaldialogues.inSanofi Genzyme expands offices in United States
This allowed Sanofi expanded to not only expand its vaccine portfolio but expand its U.S. presence by leveraging non-egg-based manufacturing technologies.
Jan 1, 2022 | globenewswire.comSanofi Genzyme partnered with Seagen on Mar 15th 22'.
Two weeks ago, Sanofi partnered with SeaGen to make antibody-drug conjugates, a type of tumor-targeting medicine that has been the at the center of several industry deals in recent years.
Jan 1, 2022 | biopharmadive.comSanofi Genzyme launches FAMhealthy
Since COVID-19 made it almost impossible for families to hold face-to-face consults with medical experts, Sanofi launched “FAMhealthy,” a series of webinars where families could get medical tips and advice.
Jan 1, 2022 | daddydoodledoo.comSanofi Genzyme is developing IgM antibody agonists against oncology
Sanofi and IGM announce partnership to develop IgM antibody agonists against oncology and immunology/inflammation targets.
Jan 1, 2022 | biopharma-reporter.comSanofi Genzyme acquires Eloctate
– For instance, in April 2018, Servier acquired Shire's oncology business to gain direct commercial access in the U.S. – Additionally, in January 2018, Sanofi announced its plan to acquire ELOCTATE.
Jan 1, 2022 | digitaljournal.comIndie Bio partners with Sanofi Genzyme
Indie Bio is delighted to work in collaboration with Sanofi in novel antibody research with its differentiated approach.”
Jan 1, 2022 | indiebio.coAmgen Foundation, Inc. partners with Sanofi Genzyme
Two are already on the market, from Amgen and Regeneron, partnered with Sanofi.
Jan 1, 2022 | cnbc.comSanofi Genzyme invests into Gyroscopetx in $60M
Sanofi is investing up to $60 million in a UK based gene therapy start up, Gyroscope Therapeutics.
Jan 1, 2021 | imapac.comSanofi Genzyme launched Diversity, Equity & Inclusion Board on Apr 4th 22'.
Sanofi launches today its Diversity, Equity & Inclusion (DE & I) Board, the first -of-its-kind in the pharmaceutical industry to feature outside advisors.
Jan 1, 2022 | biospace.comSanofi Genzyme launches DE&I iniative
Sanofi launched its DE&I iniative in June 2021, when it set a target date of 2025 to have what it called “representative leadership.”
Jan 1, 2022 | fiercepharma.comSanofi Genzyme is developing anti-IL-33 antibody, itepekimab
Sanofi and Regeneron, marketer of asthma heavy hitter Dupixent, is working on an anti-IL-33 antibody, itepekimab, for COPD.
Jan 1, 2022 | fiercebiotech.comAlphamabonc partnered with Sanofi Genzyme on Jun 1st 20'.
For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, for investigating KN026 in combination with other drugs for the treatment of HER2 breast cancer.
Jan 1, 2022 | einnews.comSanofi Genzyme decreases headcount by 25
In a New York State filing, Sanofi says it's laying off 25 Kadmon employees as it closes the site at 450 East 29th in New York City.
Jan 1, 2022 | fiercepharma.comSanofi Genzyme launched Dupixent on Mar 1st 17'.
A more immediate threat: Sanofi and Regeneron introduced Dupixent, an IL-4 and IL-13 blocker, for the treatment of more severe eczema cases in March.
Jan 1, 2017 | fiercepharma.comSanofi Genzyme is developing agonist antibodies for cancer and inflammatory diseases
Sanofi will pay IGM Biosciences $150 million and potentially billions more in milestone payments as part of a deal to develop agonist antibodies for cancer and inflammatory diseases.
Jan 1, 2022 | acs.orgSanofi Genzyme went public on Jan 1st 22'.
Sanofi plans an initial public offering for the firm on the Euronext Paris stock exchange by 2022.
Jan 1, 2020 | acs.orgVoluntis partnered with Sanofi Genzyme on Mar 1st 17'.
In March, Paris-based Voluntis expanded its partnership with Sanofi to run pilot programs based on the Insulia platform in North America and Europe.
Jan 1, 2017 | fiercebiotech.comSanofi Genzyme launched mRNA Centre of Excellence on Jan 1st 21'.
In 2021, the healthcare company Sanofi launched its mRNA Centre of Excellence.
Jan 1, 2022 | technologynetworks.comSanofi Genzyme is developing DTx app to improve mental health in patients with multiple sclerosis on Jan 1st 19'.
In 2019, Sanofi partnered with Happify Health to produce a DTx app to improve mental health in patients with multiple sclerosis.
Jan 1, 2022 | appliedclinicaltrialsonline.comSanofi Genzyme identified as competitor of Biontech on Jan 1st 21'.
In January 2021, French drug company Sanofi joined the partnership and agreed to manufacture 125 million doses, despite being a direct competitor of BioNTech.
Jan 1, 2022 | entrepreneur.comSanofi Genzyme launches hypoglycemia study on Toujeo
Also at ADA, Sanofi unveiled its own hypoglycemia study on Toujeo, based on real-world evidence gleaned on that drug, plus two Novo Nordisk basal insulins and Sanofi’s Lantus.
Jan 1, 2017 | fiercepharma.comSanofi Genzyme acquired Genzyme for $5M on Apr 14th 22'.
Genzyme, which was later bought by Sanofi, sought a refund of $5 million in franchise taxes it paid from 2004 to 2010.
Jan 1, 2022 | bloomberglaw.comSanofi Genzyme invests into assets : mRNA Center of Excellence in the amount of $3.2B
After collaborating with Translate Bio on an mRNA platform in 2018, Sanofi purchased the company for $3.2 billion last year and established a first-of-its-kind mRNA Center of Excellence.
Jan 1, 2022 | forbes.comSanofi Genzyme partnered with Formula 1 on Apr 26th 22'.
The French pharma has partnered with the Formula One racing team to boost "efficiency and performance in support of the company’s ambition to attain world-class standards of manufacturing,” Sanofi said Tuesday.
Jan 1, 2022 | fiercepharma.comSanofi Genzyme partnered with McLaren Automotive on Apr 28th 22'.
Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company’s ambition to attain world-class standards of manufacturing excellence.
Jan 1, 2022 | sciencebusiness.netSanofi Genzyme is developing Covid vaccine
Glaxo is also developing a separate Covid vaccine with French drugmaker Sanofi.
Jan 1, 2022 | bloomberg.comSanofi Genzyme will expand facilities to Singapore, Singapore on Jun 1st 22'.
DE) and Sanofi(SASY.PA) have announced plans to invest in production sites in Singapore.
Jan 1, 2022 | compsmag.comTerranbiosciences partners with Sanofi Genzyme
US biotech Terran Biosciences, which is focussed on therapeutics for neurological and psychiatric diseases, has entered into an agreement with French pharma major Sanofi (Euronext: SAN) for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
Jan 1, 2022 | thepharmaletter.comAstraZeneca plc partners with Sanofi Genzyme
AstraZeneca has also teamed up with Sanofi in the hopes of producing a vaccine, which would help the company recoup lost revenue.
Jan 1, 2022 | ukinvestormagazine.co.ukAstraZeneca plc partners with Sanofi Genzyme
AstraZeneca has also teamed up with Sanofi in the hopes of producing a vaccine, which would help the company recoup lost revenue.
Jan 1, 2022 | ukinvestormagazine.co.ukMirati Therapeutics, Inc. partners with Sanofi Genzyme
In addition to this, Mirati Therapeutics also announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib with Sanofi's investigational SHP2 inhibitor SAR442720 (RMC-4630).
Jan 1, 2022 | globenewswire.comDenali Therapeutics Inc. partners with Sanofi Genzyme
2 SAR443820, previously known as DNL788, was developed by scientists at Denali Therapeutics, which entered into a partnership with Sanofi to develop and commercialize the class of therapies in late 2018.
Jan 1, 2022 | neurologylive.comSanofi Genzyme invests into assets : production site in the amount of $1.3B
Sanofi is investing €900 million (S$1.3 billion) over five years to create two such facilities globally – one in France and the $638 million production site in Tuas, Singapore, which will allow it to quickly pivot to making new vaccines that might be needed to combat future pandemics.
Jan 1, 2022 | europeanpharmaceuticalreview.comSanofi Genzyme filed suit against Merck on Sep 1st 16'.
Sanofi sued Merck for patent infringement last September, triggering an automatic 30-month stay under the Hatch-Waxman Act, which governs generic drugs’ path to market.
Jan 1, 2017 | fiercepharma.comSanofi Genzyme is developing improved tissue-selective adeno-associated virus on Feb 1st 21'.
In February 2021, SIRION Biotech GmbH, has signed a license and collaboration agreement with Sanofi, to develop improved tissue-selective adeno-associated virus (AAV).
Jan 1, 2022 | medgadget.comSanofi Genzyme invested into Psulvalumni in $10K on Dec 1st 21'.
Penn State Lehigh Valley received a $10,000 grant from Sanofi in December to support its Student Emergency Fund and LionShare Food Pantry.
Jan 1, 2021 | psu.eduSanofi Genzyme launches Foundation S. Using donations
Sanofi has launched a pioneering funding spin-out called Foundation S. Using donations, partnerships and collective action, the project will concentrate on three critical areas – childhood cancer, the health of communities that are most vulnerable to climate change and access to life-saving treatment.
Jan 1, 2022 | pmlive.comSanofi Genzyme is developing antibody therapy that could vaccinate newborns to prevent RSV disease
In addition to the vaccines, Sanofi and AstraZeneca are working on an antibody therapy that could vaccinate newborns to prevent RSV disease.
Jan 1, 2022 | biospace.comNazem Atassi leaves Sanofi Genzyme as global head of early neurology development
“ALS is a devastating neurodegenerative disease for which effective treatment options are a critical unmet medical need,” Nazem Atassi, MD, the global head of early neurology development at Sanofi, said in a press release.
Jan 1, 2022 | alsnewstoday.comKymera Body Board, LLC partners with Sanofi Genzyme
Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immuno-oncology fields.
Jan 1, 2022 | biospace.comSanofi Genzyme hired Zerhouni as scientific advisor to the Chief Executive Officer on Jan 1st 09'.
Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011.
Jan 1, 2018 | globenewswire.comSanofi Genzyme partnered with Nhtheraguix on Feb 1st 19'.
Key Highlights From The Report In February 2019, Sanofi entered into a definitive agreement with NH TherAGuIX for the introduction of AGuIX ® Nanoparticle in the field of cancer treatment.
Jan 1, 2022 | einnews.comPfizer, Inc. partnered with Sanofi Genzyme on Dec 1st 16'.
In December 2016, Pfizer launched an app in order to support patients with depression.The New York health system announced that it will be partnering with Sanofi and digital health company Sema4 on the remote monitoring program.
Jan 1, 2022 | digitaljournal.comMcDermott leaves Sanofi Genzyme as Vice President of Human Resources
McDermott joins Rafael from Sanofi, where she served as Vice President of Human Resources.
Jan 1, 2019 | newarkonline.usSanofi Genzyme is developing Achieve Control
And in the U.S., Sanofi is working on Achieve Control, which will investigate patients naïve to insulin who are randomized to receive either Toujeo or a comparator.
Jan 1, 2017 | fiercepharma.comSanofi Genzyme is developing Aubagio
Sanofi was developing its own MS drug, Aubagio (teriflunomide), at the time.
Jan 1, 2019 | biospace.comBiond Biologics partnered with Sanofi Genzyme on Jan 1st 21'.
Biond's clinical I-O program, BND-22 (SAR444881), is an Ig-Like Transcript 2 (ILT2) receptor-blocking antibody that was partnered with Sanofi.
Jan 1, 2022 | prnewswire.comSanofi Genzyme launched subscription model to allow diabetes patients access to insulins on Apr 10th 19'.
Sanofi on Wednesday unveiled a new subscription model to allow diabetes patients access to its insulins.
Jan 1, 2019 | fiercepharma.comSanofi Genzyme launched Zantac 360° on Jun 23rd 21'.
9 Recognizing this need, Sanofi Consumer Healthcare has launched Zantac 360°™, formulated with famotidine, available as of spring 2021.
Jan 1, 2021 | pharmacytimes.comSanofi Genzyme is developing BND-22 on Jan 1st 22'.
The company entered an exclusive global licence agreement with Sanofi in January last year to develop and market BND-22.
Jan 1, 2022 | clinicaltrialsarena.comSanofi Genzyme launched Exhibit 99.1 on Mar 31st 22'.
On March 31, 2022, Sanofi published the Information Statement attached hereto as Exhibit 99.1, which is incorporated herein by reference.
Jan 1, 2022 | streetinsider.comApple Inc. partners with Sanofi Genzyme
EUROAPI has expanded a collaboration with Sanofi, which will see it support Sanofi's mRNA vaccine platform with the development of lipid nanoparticles.
Jan 1, 2022 | biopharma-reporter.comSanofi Genzyme sells assets to Rallybio LLC
Rallybio, a New Haven biotech, has acquired from Sanofi worldwide exclusive rights to develop a drug candidate designed to treat patients with severe anemia from certain blood disorders.
Jan 1, 2022 | bioct.orgSanofi Genzyme partnered with MyoKardia Inc. on Nov 1st 21'.
Similarly, in November 2021, Sanofi has partnered with MyoKardia, both in partnership will develop and discover targeted therapeutics to treat patients with genetic heart disease.
Jan 1, 2022 | openpr.comSanofi Genzyme acquired Cialis on Jun 1st 21'.
Sanofi acquired the licensing to sell Cialis as an over-the-counter treatment years ago from Eli Lilly.
Jan 1, 2022 | fiercepharma.comSanofi Genzyme sells assets to Regeneron in the amount of $1.1B
(Bloomberg) -- Regeneron Pharmaceuticals Inc. agreed to buy the immune-oncology drug Libtayo from partner Sanofi for as much as $1.1 billion, revisiting a deal that helped the French company re-enter the field of cancer research.
Jan 1, 2022 | yahoo.comSanofi Genzyme launched 16 Vaccine on Jun 1st 21'.
When Sanofi launched its “16 Vaccine” campaign several years ago, it wanted to address the lag in meningitis booster shots that was happening around age 16.
Jan 1, 2022 | endpts.comSanofi Genzyme launched Action 2022 on Jun 3rd 22'.
Sanofi today launches Action 2022, its global employee share ownership plan, open to 86 000 employees in 59 countries.
Jan 1, 2022 | thepharmadata.comSanofi Genzyme launches Digital Accelerator
Sanofi announces the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company.
Jan 1, 2022 | sanofi.comSanofi Genzyme partners with Medidata Solutions
Sanofi announced a huge $5.3 billion collaboration with Exscientia in drug discovery, while Thermo Fisher Scientific announced it was partnering with Medidata Acorn AI to optimize clinical trials.
Jan 1, 2022 | businesswire.comSanofi-Aventis (Maroc) acquired Sanofi Genzyme for $20B on Jan 1st 11'.
Genzyme, headquartered in Cambridge, was sold to French drugmaker Sanofi-Aventis in 2011 for about $20 billion.
Jan 1, 2018 | telegram.comSanofi Genzyme partners with Cara Care
Sanofi Consumer Healthcare has teamed up with digital health player Cara Care to offer an innovative treatment for IBS which goes beyond the pill and helps sufferers access personalized support for their illness.
Jan 1, 2019 | informa.comSanofi Genzyme is developing BIVV001 and fulfill an unmet need for patients with hemophilia A. Now
In a collaboration, Sanofi and Sobi are working to develop BIVV001 (efanesoctocog alfa) and fulfill an unmet need for patients with hemophilia A. Now, the collaboration has proven fruitful, as the FDA gave the drug Breakthrough Therapy Designation for this indication.
Jan 1, 2022 | biospace.comSanofi Genzyme launches Dengvaxia
When it launched Dengvaxia, Sanofi said the first-to-market vaccine had the potential to become a $1 billion product.
Jan 1, 2022 | pharmaphorum.comImmunocore Ltd partners with Sanofi Genzyme
… Immunocore (NASDAQ: IMCR), which has offices in Conshohocken; Rockville, Maryland; and Oxfordshire, England, has entered into a clinical trial collaboration and supply agreement with Sanofi.
Jan 1, 2022 | bizjournals.comSanofi Genzyme has issues with strike threat
Sanofi is facing down a strike threat in Korea amid an increasing number of confrontations between Big Pharma and their labor unions over pay demands.
Jan 1, 2022 | endpts.comSanofi Genzyme partners with Women In Tech
Additionally, Sanofi is partnering with Women in Tech® to close the gender gap in the digital health field.
Jan 1, 2021 | tmg360media.comSanofi Genzyme receives award Pharmapack 2022 Innovation Award for Eco-Design
TouStar ®, Sanofi’s new reusable pen for concentrated Toujeo ® insulin, has been recognised with the prestigious Pharmapack 2022 Innovation Award for Eco-Design.
Jan 1, 2022 | dca-design.comApple Inc partners with Sanofi Genzyme
“Apple Inc. is delighted to announce the expansion of its agreement with Sanofi for mRNA vaccines development as part of its CDMO activity.
Jan 1, 2022 | euroapi.comSanofi Genzyme has issues with recall on the product
After years of marketing Zantac as a common, over-the-counter antacid, Sanofi issued a recall on the product after it was found that ranitidine contained N-Nitrosodimethylamine (‘NDMA’) — a probable human carcinogen.
Jan 1, 2022 | sflinjuryattorneys.comSanofi Genzyme will increase headcount by 100 on Jan 1st 25'.
To support this new center, Sanofi is hiring over 100 highly-skilled tech employees, with the goal to have a 200-strong workforce by 2025.
Jan 1, 2022 | biospace.comSanofi Genzyme invests into Happify, Inc.
Sanofi invested in the app Happify Health to aid MS (multiple sclerosis) patients to aid them in conditions such as anxiety and depression.
Jan 1, 2022 | einnews.comSanofi Genzyme launches positive data from vaccine trial
Sanofi and GSK have announced positive data from their vaccine trial which evaluated an adjuvanted Beta vaccine candidate.
Jan 1, 2022 | pharmatimes.comRetail Pharmacy partners with Sanofi Genzyme
“Retail Pharmacy is excited to partner with Sanofi to be the first pharmacy group to deliver the Thrive diabetes training program.
Jan 1, 2022 | retailpharmacymagazine.com.auSkyhawktx partners with Sanofi Genzyme
PARIS and BOSTON, July 5, 2022 /PRNewswire/ -- Skyhawk Therapeutics, Inc. today announced the signing of an exclusive worldwide collaboration agreement with Sanofi to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets.
Jan 1, 2022 | prnewswire.comSanofi Genzyme launches non-profit project
French pharma major Sanofi (Euronext: SAN) has launched a new non-profit project designed to help at-risk populations in the world’s least developed countries.
Jan 1, 2022 | thepharmaletter.comSanofi Genzyme sold assets to Baxter on Dec 1st 19'.
For instance: in December 2019, Baxter’s has acquired the Seprafilm adhesion barrier and other shares from Sanofi, which is a major key player in the market; this strategy will strengthen the company’s presence in this market.
Jan 1, 2022 | designerwomen.co.ukSanofi Genzyme launches Impact
Sanofi Global Health announce s the launch of Impact ®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries.
Jan 1, 2021 | itbusinessnet.comSanofi Genzyme launches Insulin Glargine Injection U-100
Sanofi also recently launched Insulin Glargine Injection U-100 at a price that is 60% less than the current Lantus list price.
Jan 1, 2022 | ospdocs.comSanofi Genzyme is developing COVID-19 vaccine
The American Society of Transplantation (AST) and United Network of Organ Sharing (UNOS), for example, list vaccine manufacturing giant Sanofi—which partnered with both Pfizer and Johnson & Johnson to produce the COVID-19 vaccine—among their corporate sponsors.
Jan 1, 2022 | loveworlduk.orgSanofi Genzyme has issues with securities fraud or other unlawful business practices
The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | prnewswire.comSanofi Genzyme launches version of Lantus
To arrest declining MS in Insulin Glargine in the US, Sanofi launched unbranded version of Lantus, which can potentially slow down Biocon’s MS ramp-up.
Jan 1, 2022 | indiainfoline.comSanofi Genzyme is developing Solution for Blinding Syringes used during clinical study Trials
Schreiner MediPharm and Sanofi develop innovative labeling Solution for Blinding Syringes used during clinical study Trials.
Jan 1, 2016 | ncpahindia.comSanofi Genzyme launches Yseop
Sanofi are partnering with AI firm, Yseop, to use AI to automate parts of clinical trial report writing.
Jan 1, 2022 | asandk.comSanofi Genzyme launches Infusion Squad
For entertainment and education during the infusion process for children and their caregivers, Sanofi launched the audio adventure series, Infusion Squad, available as an Amazon Alexa voice skill for patients in the U.S.
Jan 1, 2022 | kelleycom.comSanofi Genzyme sold assets to Neuraxpharm Group on Jul 12th 22'.
Neuraxpharm Group (“Neuraxpharm”) today announced that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi.
Jan 1, 2022 | neuraxpharm.comSanofi Genzyme launched Zantac 360 on Jan 1st 20'.
In 2020, Sanofi introduced Zantac 360, an H2 blocker formulated with the active ingredient famotidine - the same active ingredient used in the challenger’s Pepcid products.
Jan 1, 2022 | bbbprograms.orgLee leaves Sanofi Genzyme
View the full release here: https://www.businesswire.com/news/home/20220713005323/en/ Mr. Lee joins BeiGene from Sanofi and will bring his significant expertise leading legal functions in the biopharma industry to overseeing legal, compliance, intellectual property and related matters.
Jan 1, 2022 | beigene.comSanofi Genzyme launches DE&I board
Gilead also scored highly on LGTBQ+ equality, while Sanofi’s launch of a DE&I board and an employee resource group framework also stood in its favour.
Jan 1, 2022 | pharmaphorum.comLin leaves Sanofi Genzyme as Head of Checkpoint immunology cluster in Immunology and Inflammation Research Area
Dr. Lin joins PharmaEssentia from Sanofi in Boston where she was the Head of Checkpoint immunology cluster in Immunology and Inflammation Research Area.
Jan 1, 2022 | businesswire.comSanofi Genzyme partnered with Harding University on Jul 29th 22'.
Sanofi this week announced it was partnering with the Howard University College of Pharmacy to hire full-time employees straight from the historically black college.
Jan 1, 2022 | fiercepharma.comSanofi Genzyme partners with Howard University
Sanofi has announced a collaboration with Howard University College of Pharmacy for a two-year post-professional Doctorate in Pharmacy fellowship program.
Jan 1, 2022 | appliedclinicaltrialsonline.comOptum partners with Sanofi Genzyme
Optum, Sanofi team to make low-cost insulin available to uninsured Optum, a UnitedHealth Group subsidiary, is partnering with Sanofi to make low-cost insulin available to diabetes patients without insurance.
Jan 1, 2022 | mayocliniclabs.comSanofi Genzyme is developing small molecules that modulate RNA on Jul 9th 22'.
Last month, Skyhawk revealed that Sanofi would pay it $54 million upfront and potentially up to $2 billion or more to develop small molecules that modulate RNA splicing for oncology and immunology targets.
Jan 1, 2022 | bizjournals.comPrellis Biologics, Inc. partnered with Sanofi Genzyme on Aug 10th 22'.
Earlier this year, Prellis Bio announced collaboration and licensing option agreements with Sanofi and Bristol Myers Squibb.
Jan 1, 2022 | finsmes.comInnovent Biologics partners with Sanofi Genzyme
(skegbydave/iStock/Getty Images Plus) After a PD-1 collaboration with Eli Lilly, Innovent Biologics has formed another oncology alliance with Sanofi in China.
Jan 1, 2022 | fiercepharma.comSanofi Genzyme partnered with National Institute for Health Care Management on Aug 12th 22'.
Sanofi (EURONEXT: SAN and NASDAQ: SNY) and the National Institute for Health and Care Research (NIHR) have today announced that the first patient has been enrolled in the H ospit a lised R SV Mon oclonal Ant i body Pr e vention (HARMONIE) study.
Jan 1, 2022 | businesswire.comBoehringer Ingelheim GmbH sells assets to Sanofi Genzyme
After Sanofi acquired the antacid from its original developer Boehringer Ingelheim in a 2017 asset swap, the company pulled the med from the U.S. market in 2019.
Jan 1, 2022 | fiercepharma.comSanofi Genzyme is developing protein-based vaccine on Aug 15th 21'.
Meanwhile, Sanofi and partner GSK are working on a protein-based vaccine that targets the Beta subvariant, which dominated for some time last year.
Jan 1, 2022 | begadistrictnews.com.auSanofi Genzyme invests into assets : R&D collab in the amount of $750M
Sanofi in fact had the option to buy the biotech but dropped this in favor of a $750 million R&D collab across a number of programs a few years back.
Jan 1, 2022 | fiercebiotech.comSRI International partnered with Sanofi Genzyme on Aug 17th 22'.
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence... SRI International (SRI) today announced that the company has entered a research collaboration with Sanofi.
Jan 1, 2022 | drugdiscoveryonline.comSanofi Genzyme is developing immunoglobulin M antibody agonists on Mar 1st 22'.
In March, Sanofi signed an exclusive global partnership agreement with IGM Biosciences to develop immunoglobulin M antibody agonists for oncology, immunology and inflammation targets.
Aug 20, 2022 | borderless.netSanofi Genzyme is developing Libtayo to Regeneron on Jun 1st 22'.
In June 2022, the companies signed a new agreement where Sanofi will transfer its rights to develop and commercialize Libtayo to Regeneron.
Aug 21, 2022 | dealforma.comSanofi Genzyme hires Frederic Oudea as non-executive chairman
PARIS (Reuters) - The appointment of Societe Generale (OTC:SCGLY)'s boss Frederic Oudea as non-executive chairman of Sanofi (NASDAQ:SNY) will be proposed at the next...
Aug 26, 2021 | investing.comPesquin left Sanofi Genzyme as North America head for general medicines on Aug 9th 22'.
Pesquin joins Amneal from Sanofi, where he served leadership roles of increasing responsibility over his 11-year tenure, including most recently as North America head for general medicines.
Sep 9, 2022 | drugstorenews.comSanofi Genzyme hired Frédéric Oudéa on Sep 2nd 22'.
The Board of Directors of Sanofi met on September 2, 2022 and unanimously appointed Frédéric Oudéa as ‘ Censeur ’ (non-voting member) of the Board with immediate effect.
Sep 4, 2022 | neclink.comSanofi Genzyme is developing Covid-19 shot
Recent positive developments for biopharma giant GSK include teaming up with French pharma company Sanofi to develop a new Covid-19 shot.
Aug 26, 2022 | cmcmarkets.comSanofi Genzyme is developing Beyfortus
Sanofi and AstraZeneca are jointly developing Beyfortus.
Sep 17, 2022 | worldpharmatoday.comSanofi Genzyme partnered with Tiger Pistol Inc. on Sep 21st 22'.
"By partnering with Tiger Pistol, Sanofi now has a powerful solution for scaling collaborative advertising with their partners, while gaining a deeper understanding of how customers interact with its network of independent pharmacies."
Sep 21, 2022 | ksn.comAmerican Nurses Association partnered with Sanofi Genzyme on Sep 20th 22'.
Today, the American Nurses Association ( ANA ) in collaboration with Sanofi and actor Jason Alexander have launched the Not Today, Flu national flu vaccination campaign.
Sep 20, 2022 | looktothestars.orgAbbott Laboratories Inc partnered with Sanofi Genzyme on Sep 1st 19'.
For instance, in September 2019, Abbott entered into a non-exclusive partnership with Sanofi to integrate cloud-connected insulin pens (Sanofi) with FreeStyle Libre mobile application (Abbott) to ease the management process of diabetes.
Sep 20, 2022 | benzinga.comSanofi Genzyme acquired Medivation, Inc. for $9.3B on Apr 5th 18'.
The French drug company Sanofi said on Thursday that it had made a nonbinding offer to acquire the prostate cancer drug maker Medivation for about $9.3 billion in cash.
Mar 28, 2018 | nytimes.comSanofi Genzyme partners with Lung
Sanofi and the American Lung Association (ALA) are unflinchingly dealing with this raw horror in a new awareness push for RSV.
Sep 20, 2022 | fiercepharma.comSanofi Genzyme has issues with potential breaches of fiduciary duties
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Sanofi.
Sep 15, 2022 | openpr.comSanofi Genzyme merged with Aetion, Inc. on Jan 1st 19'.
In 2019, the french durgmaker Sanofi merged its real world data platform-DARWIN with Aetion to better understand the effectiveness, safety and value of its drugs.
Apr 6, 2020 | startupcorner.ioTeam Kinguin S.A partners with Sanofi Genzyme
Team Kinguin has partnered with pharmaceutical giant Sanofi to produce a campaign for its Magne B6 supplement.
Nov 1, 2018 | esportsobserver.comGenetic Alliance partnered with Sanofi Genzyme on Mar 8th 19'.
Genetic Alliance and Gaucher Australian and New Zealand have partnered with Sanofi to host a special photographic exhibition for Rare Disease Day on 7 March 2019.
Feb 24, 2019 | oiaustralia.org.auScribetx partners with Sanofi Genzyme
Californian genetic medicine company Scribe Therapeutics has scored a major strategic collaboration with French giant Sanofi (Euronext: SAN).
Sep 27, 2022 | thepharmaletter.comSanofi Genzyme receives award Best Flexible Working Initiative award category
“Sanofi is delighted to be awarded as runner-up for the Best Flexible Working Initiative award category.”
Sep 29, 2022 | martechmetrix.comSanofi Genzyme is developing CRISPR-based cell therapies to fight cancer on Sep 27th 22'.
[Scribe Therapeutics] Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today.
Sep 27, 2022 | genengnews.comSanofi Genzyme launches Lantus
The two biggest innovations in insulin came when Sanofi launched Lantus which at the time was the first and only long-acting insulin.
Sep 22, 2022 | diabeticinvestor.comMirecule partnered with Sanofi Genzyme on Oct 4th 22'.
miRecule, Inc., an innovator of next-generation RNA therapeutics, today announced a strategic collaboration and exclusive license agreement with Sanofi to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Oct 4, 2022 | businesswire.comTrialSpark, Inc. partnered with Sanofi Genzyme on Apr 10th 22'.
TrialSpark today announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently.
Apr 9, 2022 | cmocro.comSanofi Genzyme partners with Provention Bio Inc.
Sanofi is partnering with Provention Bio on a medicine that could become the first approved treatment to alter the course of Type 1 diabetes.
Oct 6, 2022 | biopharmadive.comSanofi Genzyme is developing recombinant protein-based vaccine
Shots on goal in the fight against the COVID-19 pandemic In addition to the adjuvanted recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio.
May 16, 2021 | sanofi.comSanofi Genzyme is developing messenger RNA vaccine
Shots on goal in the fight against the COVID-19 pandemic In addition to the adjuvanted recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio.
May 26, 2021 | sanofi.comMedical Academic partnered with Sanofi Genzyme on Sep 29th 22'.
On 29 September, in partnership with Sanofi, Medical Academic hosted a webinar presented by UCT/Groote Schuur’s Prof Dirk Blom entitled ‘Lowering cholesterol: Why, when and how?’
Jun 9, 2022 | medicalacademic.co.zaSanofi Genzyme is developing novel treatment for FSHD on Oct 4th 22'.
miRecule, Inc., a biotech based in Gaithersburg, Maryland, today announced a strategic collaboration and exclusive license agreement with pharmaceutical giant Sanofi to develop and commercialize a novel treatment for FSHD.
Oct 3, 2022 | fshdsociety.orgANA partnered with Sanofi Genzyme on Oct 17th 21'.
The ANA had teamed up with Sanofi on a similar campaign, starring actor Jennifer Grey, last year.
Oct 17, 2022 | mediapost.comWayne State University Law School partners with Sanofi Genzyme
The trial sponsor Barbara Anne Karmanos Cancer Institute is affiliated with Wayne State, which was partnered with Sanofi.
Sep 12, 2016 | naturalnews.comSanofi Genzyme has issues with urgent recall notice for two contaminated batches of Targocid 200mg powder
Sanofi has issued an urgent recall notice for two contaminated batches of Targocid 200mg powder for solution for injection/infusion or oral solution, the MHRA has said.
Oct 20, 2022 | thepharmacist.co.ukAtomwise Inc. partnered with Sanofi Genzyme on Jul 17th 20'.
Atomwise, which focuses on using artificial intelligence (AI) to discover new drugs, inked a strategic research-and-development deal with Sanofi, in which the companies will use the AtomNet platform to identify and research up to five drug targets.
Aug 16, 2022 | biospace.comSanofi Genzyme invests into assets : end-to-end vaccine manufacturing facility in the amount of $900M in Toronto, Canada
The news follows Sanofi’s commitment to a $900 million end-to-end vaccine manufacturing facility in Toronto.
Sep 25, 2022 | siteselection.comMoveplangroup partners with Sanofi Genzyme
MovePlan has been working with Sanofi for the past two years to deliver move and change management programs for the new headquarter campus.
Aug 24, 2022 | moveplangroup.comRegulus Therapeutics Inc. partnered with Sanofi Genzyme on Feb 24th 22'.
The recruitment of participants for RG-012 clinical studies will be temporarily discontinued until Regulus redefines its collaboration with Sanofi, with whom it is conducting the Phase 2 HERA study ( NCT02855268 ).
Feb 23, 2022 | alportsyndromenews.comSanofi Genzyme is developing monoclonal antibody treatment
AstraZeneca and Sanofi are jointly working on a monoclonal antibody treatment that could be given to infants and children to prevent severe disease.
Nov 18, 2022 | yahoo.comSanofi Genzyme acquired Horizon Therapeutics plc on Nov 29th 22'.
Amgen, J&J’s Janssen and Sanofi are all in talks to acquire Horizon Therapeutics, the rare disease biotech disclosed late Tuesday.
Nov 23, 2022 | endpts.comSanofi Genzyme receives award 2022 Legal Procurement Teamwork Award
PERSUIT and Sanofi, as pioneers of legal procurement, received the 2022 Legal Procurement Teamwork Award from Buying Legal® Council.
Oct 24, 2022 | persuit.comSanofi Genzyme launches therapeutic vaccine candidate for acne vulgaris based on recombinant proteins
With this purchase, Sanofi expanded its portfolio of early-stage products to include ORI-001, a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins.
Nov 24, 2022 | medgadget.comSanofi Genzyme launches COVID-19 vaccine
(libre de droit/iStock/Getty Images Plus) Sanofi and GlaxoSmithKline showed their recombinant adjuvanted COVID-19 vaccine works well as a booster.
Dec 10, 2021 | fiercepharma.comSanofi Genzyme hired Valeria on Jan 1st 21'.
Valeria joined Sanofi in 2021 and has more than 16 years of industry experience in exploratory biology and oncology drug discovery and development.
Nov 29, 2022 | medcitynews.comSanofi Genzyme launches Humanitarian Program
Recognizing that problem, Genzyme (now Sanofi) launched a Humanitarian Program to make its enzyme replacement therapies accessible to all patients as soon as the first such therapy, for Gaucher disease, received FDA approval in 1991.
Nov 29, 2022 | yale.eduSanofi Genzyme is developing recombinant Covid-19 vaccine
The market cap for the company is $114,099m. Find out more information at: https://www.sanofi.com Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange.
Dec 4, 2022 | directorstalkinterviews.comSanofi Genzyme partners with Griffith University
Queensland will become a global mRNA vaccine hub with leading healthcare company Sanofi partnering with Griffith University and other leading research institutions to establish a world-first research centre in south east Queensland.
Dec 5, 2022 | griffith.edu.auSanofi Genzyme is developing mRNA vaccines in the Sunshine State
The world’s first chlamydia vaccine is set to be developed in Queensland after French pharmaceutical giant Sanofi signed on to develop a number of new mRNA vaccines in the Sunshine State.
Dec 5, 2022 | 7news.com.auSanofi Genzyme files suit against Apotex Inc.
Sanofi originally sued Apotex and other defendants in D.N.J.
Dec 9, 2022 | jdsupra.comSanofi Genzyme partnered with Innate Pharma SA on Jan 1st 16'.
Sanofi and Innate Pharma first partnered in 2016 to develop two bispecific NK cell engagers.
Dec 18, 2022 | biospace.comDoug leaves Sanofi Genzyme as Senior Vice President and General Manager, Head of Renal (kidney) Global Business Unit
Doug also came from Sanofi where he was Senior Vice President and General Manager, Head of Renal (kidney) Global Business Unit.
Dec 11, 2022 | internetstockreview.comSanofi expanded offices to Paris, France on Nov 28th 22'.
On November 28, 2022, it was reported, ‘Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability.’
Jun 9, 2022 | tapanray.inSanofi recognized as Dividend Channel ''International S.A.F.E. 10
Sanofi (Symbol: SNY) has been named to the Dividend Channel ''International S.A.F.E. 10'' list, signifying an international stock with above-average ''DividendRank'' statistics including a strong 3.6% yield, as well as a superb track record of at least five years of dividend growth, according to the most recent ''DividendRank'' report.
Dec 27, 2022 | nasdaq.com